Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.831
-0.056 (-6.36%)
At close: Dec 20, 2024, 4:00 PM
0.830
-0.001 (-0.12%)
After-hours: Dec 20, 2024, 6:45 PM EST
Company Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.
The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG.
The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.
| Country | Canada |
| Founded | 1998 |
| IPO Date | Nov 8, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Wayne Pisano |
Contact Details
Address: 322 11th Avenue SW, Suite 804 Calgary, AB T2R 0C5 Canada | |
| Phone | 403 670 7377 |
| Website | oncolyticsbiotech.com |
Stock Details
| Ticker Symbol | ONCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| CIK Code | 0001129928 |
| CUSIP Number | 682310875 |
| ISIN Number | CA6823108759 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Matthew C. Coffey M.B.A., Ph.D. | President, Chief Executive Officer and Director (Leave of Absence) |
| Wayne F. Pisano M.B.A. | Interim Chief Executive Officer and Chairman of the Board |
| Kirk J. Look C.A., CA | Chief Financial Officer |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development |
| Amy Goodowitz Levin B.S.N., R.N. | Vice President of Clinical Operations |
| Jon Patton | Director of Investor Relations and Communication |
| John Mark Lievonen B.B.A., F.C.A., FCPA, LLD, M.B.A. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 6-K | Report of foreign issuer |
| Dec 3, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Oct 4, 2024 | 6-K | Report of foreign issuer |
| Sep 19, 2024 | 6-K | Report of foreign issuer |
| Sep 6, 2024 | 6-K | Report of foreign issuer |
| Aug 5, 2024 | SUPPL | Filing |
| Aug 2, 2024 | 6-K | Report of foreign issuer |